RÉSUMÉ
Sleep-disordered breathing (SDB), including obstructive and central sleep apnea, significantly exacerbates heart failure (HF) through adverse cardiovascular mechanisms. This review aims to synthesize existing literature to clarify the relationship between SDB and HF, focusing on the pathophysiological mechanisms, diagnostic challenges, and the effectiveness of treatment modalities like continuous positive airway pressure (CPAP) and adaptive servo-ventilation ASV. We analyzed peer-reviewed articles from 2003 to 2024 sourced from PubMed, EMBASE, Scopus, and Web of Science databases. The prevalence of SDB in HF patients is high, often underdiagnosed, and underappreciated. Management strategies, including CPAP and ASV, have been shown to mitigate symptoms and improve cardiac function. However, despite the availability of effective treatments, significant challenges in screening and diagnosis persist, affecting patient management and outcomes. DB significantly impacts HF prognosis. Enhanced screening strategies and broader utilization of therapeutic interventions like CPAP and ASV are essential to improve the management and outcomes of HF patients with concomitant SDB. Future research should focus on refining diagnostic and treatment protocols to optimize care for HF patients with SDB.
Sujet(s)
Ventilation en pression positive continue , Défaillance cardiaque , Syndromes d'apnées du sommeil , Humains , Défaillance cardiaque/thérapie , Syndromes d'apnées du sommeil/thérapie , Syndromes d'apnées du sommeil/complications , Syndromes d'apnées du sommeil/diagnostic , PronosticRÉSUMÉ
BACKGROUND: This study investigated whether the chronic use of adaptive servo-ventilation (ASV) reduces all-cause mortality and the rate of urgent rehospitalization in patients with heart failure (HF). METHODSâANDâRESULTS: This multicenter prospective observational study enrolled patients hospitalized for HF in Japan between 2019 and 2020 who were treated either with or without ASV therapy. Of 845 patients, 110 (13%) received chronic ASV at hospital discharge. The primary outcome was a composite of all-cause death and urgent rehospitalization for HF, and was observed in 272 patients over a 1-year follow-up. Following 1:3 sequential propensity score matching, 384 patients were included in the subsequent analysis. The median time to the primary outcome was significantly shorter in the ASV than in non-ASV group (19.7 vs. 34.4 weeks; P=0.013). In contrast, there was no significant difference in the all-cause mortality event-free rate between the 2 groups. CONCLUSIONS: Chronic use of ASV did not impact all-cause mortality in patients experiencing recurrent admissions for HF.
Sujet(s)
Défaillance cardiaque , Réadmission du patient , Humains , Défaillance cardiaque/mortalité , Défaillance cardiaque/thérapie , Sujet âgé , Mâle , Femelle , Études prospectives , Réadmission du patient/statistiques et données numériques , Sujet âgé de 80 ans ou plus , Japon/épidémiologie , Adulte d'âge moyen , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
Rationale: Adaptive servo-ventilation (ASV) effectively treats sleep-disordered breathing, including central sleep apnea (CSA) and coexisting obstructive sleep apnea (OSA).Objectives: The prospective, multicenter European READ-ASV (Registry on the Treatment of Central and Complex Sleep-Disordered Breathing with Adaptive Servo-Ventilation) registry investigated the effects of first-time ASV therapy on disease-specific quality of life (QoL).Methods: The registry enrolled adults with CSA with or without OSA who had ASV therapy prescribed between September 2017 and March 2021. The primary endpoint was change in disease-specific QoL (Functional Outcomes of Sleep Questionnaire [FOSQ]) score between baseline and 12-month follow-up. Sleepiness determined using the Epworth Sleepiness Scale (ESS) score was a key secondary outcome. For subgroup analysis, participants were classified as symptomatic (FOSQ score < 17.9 and/or ESS score > 10) or asymptomatic (FOSQ score ⩾ 17.9 and/or ESS score ⩽ 10).Results: A total of 801 individuals (age, 67 ± 12 yr; 14% female; body mass index, 31 ± 5 kg/m2; apnea-hypopnea index, 48 ± 22/h) were enrolled; analyses include those with paired baseline and follow-up data. After 12 ± 3 months on ASV, median (interquartile range) FOSQ score had increased significantly from baseline (+0.8 [-0.2 to 2.2]; P < 0.001; n = 499). This was due to a significantly increased FOSQ score in symptomatic participants (+1.69 [0.38 to 3.05]), with little change in asymptomatic individuals (+0.11 [-0.39 to 0.54]). The median ESS score also improved significantly from baseline during ASV (-2.0 [-5.0 to 0.0]; P < 0.001).Conclusions: ASV treatment of CSA with or without coexisting OSA was associated with improvements in disease-specific QoL and daytime sleepiness, especially in individuals with sleep-disordered breathing symptoms before therapy initiation. These improvements in patient-reported outcomes support the use of ASV in this population.
Sujet(s)
Défaillance cardiaque , Syndromes d'apnées du sommeil , Apnée centrale du sommeil , Syndrome d'apnées obstructives du sommeil , Adulte , Humains , Femelle , Adulte d'âge moyen , Sujet âgé , Mâle , Qualité de vie , Études prospectives , Envie de dormir , Syndromes d'apnées du sommeil/thérapie , Syndromes d'apnées du sommeil/complications , Syndrome d'apnées obstructives du sommeil/complications , Résultat thérapeutiqueRÉSUMÉ
La apnea central del sueño es causada por una falla temporal del centro ponto-medular que es el responsable de generar una respiración rítmica. Puede ser un hallazgo fisiológico durante la transición vigilia-sueño o estar presente por múltiples causas. La enfermedad cardiovascular o cerebro-vascular, el síndrome de apneas e hipopneas obstructivas durante el sueño, el uso de opioides y el tratamiento con CPAP son las más frecuentes en la práctica clínica, mientras que en sujetos sanos las apneas centrales se relacionan con la altura durante la exposición recreacional. Este trabajo revisa la fisiopatología de las apneas centrales, su clasificación, las normas para su identificación en los estudios de sueño y un enfoque práctico sobre las opciones terapéuticas disponibles.
Central sleep apnea is caused by a temporary failure of the ponto-medullary center that is responsible for generating rhythmic breathing. It can be a physiological finding during the sleep-wake transition or be present for multiple causes. Cardiovascular or cerebrovascular disease, obstructive sleep apnea/hypopnea syndrome, use of opioids and treatment with CPAP (Continuous Positive Airway Pressure) are the most frequent in clinical practice, while in healthy subjects central apneas are related to high altitude during recreational exposure. This study reviews the physiopathology of central apneas, their classification, the current rules for their identification in sleep studies and a practical approach to the therapeutic options available.
RÉSUMÉ
Objective To evaluate the long-tem effect of adaptive servo ventilation (ASV) on patients with chronic heart failure (CHF) and sleep-disordered breathing (SDB). Methods The controlled clinical articles were searched included in PubMed, Cochrane, EMBASE and CBM, CJFD, WangFang Database from Jan. 1970 to Dec. 2015. Included standard: left ventricular ejection fraction (LVEF) ≤55%, apnea hypopnea index (AHI) ≥15/h, follow up period over 4 weeks. After quality assessment (modified Jadad score) and data extraction by two independent reviewers, mete analysis was performed with RevMan 5.3 software. Results Thirteen studies were recruited including 442 cases being followed over 4 weeks [ASV group 233 cases and control group 216 cases (corssover design 7)]. Compared to control group, LVEF increased [weighted mean difference (WMD)=3.72, 95%CI: 1.80-5.64, PP<0.01] and AHI decreased significantly (WMD=–18.63, 95%CI: –26.19-–11.08), the distance walked in 6 minutes increased (WMD=28.72, 95%CI: 2.26-55.18, P=0.03) and plasma N terminal brain natriuretic peptide precursor (NT-pro BNP) decreased significantly (WMD=–744.03, 95%CI: –1262.45-–225.62, P<0.05) in ASV group. Conclusion Over 4 weeks ASV may improve LVEF and AHI, increase 6-min walking distance and decrease NT-pro BNP in patients with CHF and SDB.